Tambet Teesalu, Ph.D.

Tambet Teesalu's Research Focus

Dr. Teesalu uses phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biological, and nanoparticles into tumors to increase their therapeutic index. His scope includes understanding the molecular interactions involved to drive specificity and activity, focusing on Tumor Penetrating Peptides (TPP) that trigger bulk extravascular transport in the tumor tissue.

Tambet Teesalu's Bio

Dr. Teesalu received his Ph.D. at University of Helsinki, Faculty of Medicine (jointly at San Raffaele Biomedical Institute in Milan, Italy) in 1999 studying the molecular mechanisms of mouse embryo implantation. He trained as a postdoctoral scientist with Antti Vaheri at the University of Helsinki, Finald until 2001. From 2001 to 2005, Dr. Teesalu was CEO of Applied Phenomics LLC, Tartu, Estonia. In 2005 he joined Dr. Ruoslahti's lab at SBP as a postdoctoral scientist and became a staff scientist. Dr. Teesalu is now an Adjunct Assistant Professor here and a Visiting Professor, Head of Laboratory of Cancer Biology at the University of Tartu, Estonia.


TMC Accessory

Publications

Mapping of vascular ZIP codes by phage display.

Teesalu T, Sugahara KN, Ruoslahti E

Methods Enzymol 2012 ;503:35-56

A high-throughput label-free nanoparticle analyser.

Fraikin JL, Teesalu T, McKenney CM, Ruoslahti E, Cleland AN

Nat Nanotechnol 2011 May ;6(5):308-13

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E

Science 2010 May 21 ;328(5981):1031-5

Show All Select Publications

Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide.

Lepland A, Asciutto EK, Malfanti A, Simón-Gracia L, Sidorenko V, Vicent MJ, Teesalu T, Scodeller P

Mol Pharm 2020 Jun 1 ;

Tumor-penetrating peptide for systemic targeting of Tenascin-C.

Lingasamy P, Tobi A, Kurm K, Kopanchuk S, Sudakov A, Salumäe M, Rätsep T, Asser T, Bjerkvig R, Teesalu T

Sci Rep 2020 Apr 2 ;10(1):5809

A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis.

Acharya B, Meka RR, Venkatesha SH, Lees JR, Teesalu T, Moudgil KD

Mol Cell Probes 2020 Jun ;51:101530

Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction.

Torrieri G, Fontana F, Figueiredo P, Liu Z, Ferreira MPA, Talman V, Martins JP, Fusciello M, Moslova K, Teesalu T, Cerullo V, Hirvonen J, Ruskoaho H, Balasubramanian V, Santos HA

Nanoscale 2020 Jan 28 ;12(4):2350-2358

Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery.

Lingasamy P, Tobi A, Haugas M, Hunt H, Paiste P, Asser T, Rätsep T, Kotamraju VR, Bjerkvig R, Teesalu T

Biomaterials 2019 Oct ;219:119373

Peptide-guided nanoparticles for glioblastoma targeting.

Säälik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, Simón-Gracia L, Hunt H, Paiste P, Kotamraju VR, Bergers G, Asser T, Rätsep T, Ruoslahti E, Bjerkvig R, Friedmann-Morvinski D, Teesalu T

J Control Release 2019 Aug 28 ;308:109-118

Show All Publications